Effectiveness and safety of alemtuzumab in the treatment of active relapsing–remitting multiple sclerosis: a multicenter, observational study-Reference-Cited by-同舟云学术

Effectiveness and safety of alemtuzumab in the treatment of active relapsing–remitting multiple sclerosis: a multicenter, observational study

Published:2021-03-03 Issue:11 Volume:42 Page:4591-4597
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Brecl Jakob Gregor,Barun Barbara,Gomezelj Sarah,Gabelić Tereza,Šega Jazbec Saša,Adamec Ivan,Horvat Ledinek Alenka,Rot Uroš,Krbot Skorić Magdalena,Habek Mario^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Clinical Neurology,Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-021-05145-x.pdf

Reference18 articles.

1. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS II investigators (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839

2. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828

3. Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, Shankara S, Roberts BL, Kaplan JM (2012) Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 7:e39416

4. Ruck T, Bittner S, Wiendl H, Meuth SG (2015) Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci 16:16414–16439

5. McCall B (2019) Alemtuzumab to be restricted pending review. says EMA. Lancet 393:1683

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alemtuzumab treatment for multiple sclerosis in Austria: An observational long‐term outcome study;Annals of Clinical and Translational Neurology;2024-05-07

2. Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis;Frontiers in Immunology;2024-04-16

3. Risk of secondary immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis;Frontiers in Neurology;2024-04-10

4. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study;CNS Drugs;2024-02-28

5. Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis;Neurology and Therapy;2023-06-29